Fabry Disease Market: Market Size and Share, Epidemiology Forecast, Treatment Landscape, Emerging Drugs and Leading Companies

iCrowd Newswire
09 Jun 2021, 08:08 GMT+10

DelveInsight's Fabry Disease Market Insights Report offers a detailed analysis of disease, its causes, symptoms, diagnostics modalities, and treatment options.

The report covers Fabry Disease epidemiology, emerging therapeutics, market dynamics, market drivers and barriers, ongoing clinical trials, important collaborations in the field, and key pharmaceutical companies actively pushing market growth forward for the study period 2017-2030 in 7MM (the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan).

Some of the key highlights from the Fabry Disease Market Insights:

- According to data from Orphanet, Fabry disease is reported to be 1 in 80,000 live births annually but this figure may underestimate disease prevalence. When late-onset variants of the disease are considered, a prevalence of approximately 1 in 3,000 is suggested.
- The US estimate for Fabry disease described in the National Institutes of Health Genetics Home Reference states Fabry disease affects an estimated 1 in 40,000 to 60,000 males.

As per Tsuboi et al, 2012 Fabry disease prevalence is higher in the males than females

In a study by Saito et al, 2016 the prevalence rate of Fabry disease in Japan Fabry disease screening study ( J-FAST) was 0.02 % with 0.04 % (2/5408) in males and 0 % (0/3139) in females.

Key players, such as Safoni Genzyme, Idorsia Pharmaceuticals, Protalix Biotherapeutics, Sangamo Therapeutics, 4D Molecular Therapeutics, and many others are involved in developing therapies for fabry disease.

Emerging therapies such as Venglustat, Lucerastat, PRX- 102, ST 920, 4D-310, and others are expected to have a significant impact on the fabry disease market in the coming years.

Learn more by requesting for sample @ Fabry Disease Market Landscape

Fabry Disease Overview

Fabry disease (FD) is a devastating, progressive, inherited condition caused by lysosomal dysfunction linked to chromosome X and mutations in the GLA gene located in chromosome Xq22.1 which encodes the alpha-galactosidase A (AGA) enzyme.

It is a multi-systemic and life-threatening condition which is one of the most common lysosomal storage diseases after the Gaucher Disease. It is characterized by specific neurological, cutaneous, renal, cardiovascular, cochleovestibular and cerebrovascular manifestations. The symptoms include Chronic pain, usually a burning or tingling sensation in the hands and feet. The pain sometimes briefly becomes more intense, requiring medication to bring it down to manageable levels. The pain can go away in adulthood, clusters of small, dark red spots in various locations on the skin, opaque corneas, resulting in cloudy-looking eyes and problems with eyesight, ringing in the ears, and hearing loss, a variety of gastrointestinal problems, decreased ability to sweat, and others.

For more insights into Disease, causes and treatment, reach out @ Fabry Disease Treatment Landscape

Fabry Disease Epidemiology Segmentation

The Fabry Disease Market report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

Fabry Disease Prevalence

Age-Specific Fabry Disease Prevalence

Gender-Specific Fabry Disease Prevalence

Diagnosed and Treatable Cases of Fabry Disease

Visit for more @ Fabry Disease Epidemiological Insights

Fabry Disease Market

The launch of various innovative medicines, important firms operating in the area, rising prevalence, more R&D in the area, and medical innovations occurring in the Fabry Disease market domain are all projected to contribute to the market's growth.

Fabry Disease Pipeline Therapies and Key Companies

Lucerastat: Idorsia Pharmaceuticals

Pegunigalsidase alfa: Protalix Biotherapeutics

AVR-RD-01: Avrobio

Venglustat: Sanofi Genzyme

ST-920: Sangamo Therapeutics

4D-310: 4D Molecular Therapeutics

For more information, visit Fabry Disease Market Analysis, Patient Pool and Emerging Therapies

Fabry Disease Market Drivers

Rising prevalent population

Technological advancements

Emerging therapies

Extensive R&D

Scope of the Report

11 Years Forecast

7MM Coverage

Descriptive overview of Fabry Disease, covering causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

Comprehensive insight into Fabry Disease epidemiology and treatment in the 7MM

Current and emerging therapies for Fabry Disease

Fabry Disease market drivers and barriers

Key Questions Answered in the Report

What was the Fabry Disease market share (percentage) distribution like in 2018 and what will it be like in 2030?

During the forecast period (2018-2030), what will be the entire market size for Fabry Disease, as well as the market size by therapy?

What are the most important results from the 7MM market, and which nation will have the largest Fabry Disease market size throughout the projected period (2018-2030)?

During the projection period (2018-2030), at what CAGR is the Fabry Disease market anticipated to expand at 7MM?

Get in touch with our Business executive @ Fabry Disease Market Landscape Analysis

Table of Contents

Key Insights

Report Introduction

Competitive Intelligence Analysis for Fabry Disease

Fabry Disease Market Overview at a Glance

Executive Summary of Fabry Disease

Fabry Disease Epidemiology and Market Methodology

Fabry Disease Epidemiology and Patient Population

Fabry Disease Patient Journey

Treatment Algorithm, Current Treatment, and Medical Practices

10.

Key Endpoints in Fabry Disease Clinical Trials

11.

Fabry Disease Marketed Therapies

12.

Fabry Disease Emerging Therapies

13.

Fabry Disease: 7 Major Market Analysis

14.

Attribute analysis

15.

Access and Reimbursement Overview of Fabry Disease

16.

KOL Reviews

17.

Case Reports

18.

Fabry Disease Market Drivers

19.

Fabry Disease Market Barriers

20.

SWOT Analysis

21.

Disclaimer

22.

DelveInsight Capabilities

23.

About DelveInsight

Learn more about the report offerings @ Fabry Disease Market Outlook

DelveInsight's 'Acute Respiratory Distress Syndrome (ARDS) - Market Insights, Epidemiology and Market Forecast - 2030' report.

Acromegaly Market

DelveInsight's 'Acromegaly-Market Insights, Epidemiology, and Market Forecast-2030' report.

Alopecia Areata Market

DelveInsight's "Alopecia Areata - Market Insights, Epidemiology, and Market Forecast-2030″ report.

Cerebral Palsy Market

DelveInsight's "Cerebral Palsy - Market Insights, Epidemiology, and Market Forecast-2030" report.

Cluster Headache Market

DelveInsight's 'Cluster Headache Market Insights, Epidemiology, and Market Forecast-2030' report.

Complex Regional Pain Syndrome (CRPS) Market

DelveInsight's 'Complex Regional Pain Syndrome (CRPS) - Market Insights, Epidemiology and Market Forecast-2030' report.

Cushing's Syndrome Market

DelveInsight's "Cushing's Syndrome - Market Insights, Epidemiology, and Market Forecast-2030" report.

Healthcare Blogs:

Angelman Syndrome Market: Insights Into The Recent Late-Stage Drug Failures And Novel Approaches To Treating This Rare Neurogenetic Disorder

Limited Therapies in the Rare Disease Pipeline: Watch out for Rare Indications that Calls Out for Novel Therapies

The Paradox of Rare: Chalking out Challenges in the Rare Disease Market

Get in touch with our Business executive for Pharma and Healthcare Market Assessment and Consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences providing end-to-end comprehensive solutions to improve their performance.

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Tags: fabrydiseasemarket, fabrydiseasemarketshare, fabrydiseasemarketsize, fabrydiseasemarkettrends, fabrydiseasetherapies, fabrydiseasekeycompanies, fabrydiseaseemergingtherapies, fabrydiseasemarketinsights